Menu
In May 2024, it will be possible to exercise the warrants of series TO6 issued in connection with the rights issue conducted in December 2023. The subscription period will run from and including May 20, 2024, up to and including May 31, 2024. Each warrant of series TO6 entitles the holder the right to subscribe for one (1) new share in Prolight Diagnostics AB. Please note that warrants of series TO6 that are not exercised at latest May 31, 2024, or sold at the least on May 28, 2024, will expire without value.
Exercise period:
May 20, 2024 – May 31, 2024.
Exercise price:
0,10 SEK per share.
Issue size:
217,513,494 warrants of series TO6 entitling to subscription of 217,513,494 shares. If all the warrants are exercised the Company will receive approximately SEK 21,8 million before issuing costs.
Last day for trading with warrants of series TO6: May 28, 2024.
Dilution:
If all warrants of series TO6 are exercised the total number of shares in the Company will increase by 217,513,494, from 499,782,948 shares to 717,296,442 shares, and the share capital will increase with SEK 21,751,349.40, from SEK 49,978,294.80, to SEK 71,729,644.20. This corresponds to a maximum dilution of approximately 30.3 percent of the total number of shares and votes in the Company.
Note that the warrants that are not exercised at latest on May 31, 2024, or sold at the latest on May 28, 2024, will expire without value. For the warrants not to lose their value, the holder must actively exercise the warrants for subscription of new shares or sell the warrants. Please observe that certain nominees might close their application earlier than May 31, 2024.
Full terms and conditions for the warrants of series TO6: Klick here!
Nominee-registered warrants (custody)
Subscription and payment by exercise of the warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Directly registered warrants (VP account)
No issue report or payment instruction will be sent out. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) pending registration at the Swedish Companies Registration Office.
The prospectus and offerings may NOT be downloaded or read by persons residing in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where participation would require additional prospectuses, registration, or measures other than those under Swedish law or otherwise contrary to the rules of such jurisdiction. Distribution of the Prospectus and offerings and participation in the Offer are subject to restrictions in law and other rules in some jurisdictions. The Company has not taken and will not take any steps to allow an offer to the public in any jurisdictions other than Sweden. The Offer is not addressed to persons domiciled in the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where participation would require additional prospectuses, registration, or other measures than those arising under Swedish law or otherwise contrary to the rules of such jurisdiction. Consequently, the prospectus, the notification form and other documents relating to the Offer may not be distributed in or to said countries or any other jurisdiction where distribution or the Offer requires such action or otherwise violates applicable rules. Subscription of units and acquisition of securities in violation of the above limitations may be invalid. Persons receiving copies of the Prospectus must inform themselves of and comply with such restrictions. Measures in breach of the restrictions may constitute a breach of applicable securities laws. You can find the documents with restricted access below.